Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2019 02:40 ET | Source: LIDDS AB

LIDDS announces a novel TLR9 agonist project and plan for Phase I clinical trial

Clinical data shows that intratumoral delivery of TLR agonists in combination with immune checkpoint inhibitors can effectively treat solid cancers. NanoZolid® technology is very suitable to provide...
March 26, 2019 03:50 ET | Source: LIDDS AB

LIDDS: NanoZolid® technology receives US patent valid until 2037

The United States Patent and Trademark Office has issued a Notice of Allowance for the NanoZolid® technology patent. This will provide additional patent protection for all LIDDS development...
March 18, 2019 03:45 ET | Source: LIDDS AB

LIDDS to evaluate a possible listing of the company's shares on Nasdaq Stockholm's Main Market during 2020

STOCKHOLM - LIDDS (Nasdaq First North: LIDDS) announced today that the company will evaluate a possible listing of its shares on Nasdaq Stockholm's Main Market during 2020 and will engage advisors...
March 13, 2019 05:04 ET | Source: LIDDS AB

LIDDS: First patient receives intratumoral NanoZolid®-docetaxel in Phase I study

The first patient has now been enrolled in the Phase I NanoZolid®-docetaxel study where NanoZolid® combined with docetaxel will be injected into solid tumors. The first injection was administered at...
March 12, 2019 05:15 ET | Source: LIDDS AB

LIDDS: NanoZolid® technology presented at Pharma R&D congress in Paris

Pharma R&D 2019 attracted a large number of academic and pharmaceutical industry delegates interested in finding new drug delivery technologies for drug products. LIDDS presented the NanoZolid®...
March 07, 2019 07:45 ET | Source: LIDDS AB

LIDDS: Collaboration with Belina Pharma concludes

A collaboration agreement with Belina was signed in 2017 with the aim of using LIDDS depot technology in combination with a drug intended for the treatment of breast cancer. The collaboration has...
March 06, 2019 02:18 ET | Source: LIDDS AB

LIDDS: Final patient enrolled in Phase IIb Liproca® Depot prostate cancer study

The last patient has been enrolled in LIDDS Phase IIb study for the localized treatment of prostate cancer. The Phase IIb study will identify the optimal dose for Phase III and test the safety of...
February 28, 2019 02:40 ET | Source: LIDDS AB

LIDDS Bokslutskommuniké 2018

OKTOBER - DECEMBER 2018 Nettoomsättningen uppgick till 0,0 (0,4) KSEK Kostnaderna uppgick till 5,0 (2,6) MSEK Resultatet före och efter skatt uppgick till -4,9 (-2,2) MSEK ...
February 06, 2019 03:08 ET | Source: LIDDS AB

LIDDS employs Head of Clinical Development

LIDDS has employed Charlotta Gauffin as Head of Clinical Development. Charlotta will join the company in March 2019 and be responsible for the Phase IIb clinical study for Liproca® Depot and the...
February 05, 2019 03:39 ET | Source: LIDDS AB

LIDDS adds another Scandinavian clinic to the NZ-DTX-001 clinical trial

UPPSALA, SWEDEN - LIDDS AB (publ) has received approval from the Danish Medicines Agency (DKMA) to conduct its Phase I NZ-DTX-001 clinical trial. The Danish study is in addition to the Phase I...